Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
58.21
-0.56 (-0.95%)
Jan 29, 2026, 10:26 AM EST
Novo Nordisk Employees
Novo Nordisk had 78,554 employees as of September 30, 2025. The number of employees increased by 6,674 or 9.28% compared to the same quarter last year.
Employees
78,554
Change
6,674
Growth
9.28%
Revenue / Employee
$631,163
Profits / Employee
$207,532
Market Cap
263.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 78,554 | 6,674 | 9.28% | 78,554 | 0 |
| Jun 30, 2025 | 78,387 | 9,127 | 13.18% | 78,387 | 0 |
| Mar 31, 2025 | 77,406 | 11,391 | 17.26% | 77,406 | 0 |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% | 76,302 | 1,047 |
| Sep 30, 2024 | 71,880 | 10,468 | 17.05% | 71,880 | 0 |
| Jun 30, 2024 | 69,260 | 9,923 | 16.72% | 69,260 | 0 |
| Mar 31, 2024 | 66,015 | 8,926 | 15.64% | 66,015 | 0 |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% | 63,370 | 949 |
| Sep 30, 2023 | 61,412 | 8,716 | 16.54% | 61,412 | 0 |
| Jun 30, 2023 | 59,337 | 8,521 | 16.77% | 59,337 | 0 |
| Mar 31, 2023 | 57,089 | 7,794 | 15.81% | 57,089 | 0 |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% | 54,393 | 792 |
| Sep 30, 2022 | 52,696 | 5,714 | 12.16% | 52,696 | 0 |
| Jun 30, 2022 | 50,816 | 4,845 | 10.54% | 50,816 | 0 |
| Mar 31, 2022 | 49,295 | 4,138 | 9.16% | 49,295 | 0 |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% | 47,792 | 686 |
| Sep 30, 2021 | 46,982 | 2,656 | 5.99% | 46,982 | 0 |
| Jun 30, 2021 | 45,971 | 2,445 | 5.62% | 45,971 | 0 |
| Mar 31, 2021 | 45,157 | 1,999 | 4.63% | 45,157 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
| OpGen | 1 |
Novo Nordisk News
- 1 day ago - 2 Beaten-Down Growth Stocks Ready to Bounce Back - The Motley Fool
- 1 day ago - Novo Nordisk: Investors May Be In For An Earnings Surprise - Seeking Alpha
- 1 day ago - Novo Nordisk AS (NVO) Trading Down 3.04% on Jan 28 - GuruFocus
- 1 day ago - Novo Nordisk Doubles U.S. Ad Spend on Wegovy, Ozempic - GuruFocus
- 1 day ago - Novo Nordisk (NVO) Outspends Lilly in U.S. GLP-1 Drug Advertising - GuruFocus
- 1 day ago - Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows - Reuters
- 1 day ago - 1 Biotech Stock Set to Rebound in 2026 - The Motley Fool
- 2 days ago - 1 Pharmaceutical Stock Set to Rebound in 2026 - The Motley Fool